Press releases
- Edwards Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability
- Edwards Lifesciences Reports First Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on April 25, 2024
- Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It
- Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR
More ▼
Key statistics
As of last trade Edwards Lifesciences Corp (EWL:FRA) traded at 80.84, -9.09% below its 52-week high of 88.92, set on Mar 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 80.50 |
---|---|
High | 81.13 |
Low | 80.50 |
Bid | 80.70 |
Offer | 81.40 |
Previous close | 83.00 |
Average volume | 680.33 |
---|---|
Shares outstanding | 602.60m |
Free float | 597.18m |
P/E (TTM) | 37.59 |
Market cap | 52.70bn USD |
EPS (TTM) | 2.33 USD |
Data delayed at least 15 minutes, as of May 24 2024 11:19 BST.
More ▼